Pattern of hepatocarcinoma recurrence in cirrhosis: The role of anatomic and parenchyma-sparing resection. A propensity score analysis

2018 ◽  
Vol 50 (1) ◽  
pp. 39
Author(s):  
S. Famularo ◽  
S. Di Sandro ◽  
A. Giani ◽  
A. Lauterio ◽  
F. Romano ◽  
...  
Keyword(s):  
Propensity Score ◽  
Propensity Score Analysis ◽  
Score Analysis ◽  
Parenchyma Sparing

scholarly journals Risk of severe maternal morbidity associated with cesarean delivery and the role of maternal age: a population-based propensity score analysis

2019 ◽  
Vol 191 (13) ◽  
pp. E352-E360 ◽  
Author(s):  
Diane Korb ◽  
François Goffinet ◽  
Aurélien Seco ◽  
Sylvie Chevret ◽  
Catherine Deneux-Tharaux ◽  
...  
Keyword(s):  
Propensity Score ◽  
Cesarean Delivery ◽  
Maternal Age ◽  
Maternal Morbidity ◽  
Propensity Score Analysis ◽  
Population Based ◽  
Severe Maternal Morbidity ◽  
Score Analysis

The role of valve surgery in infective endocarditis management: A systematic review of observational studies that included propensity score analysis

2008 ◽  
Vol 156 (5) ◽  
pp. 901-909 ◽  
Author(s):  
Imad M. Tleyjeh ◽  
Tarek Kashour ◽  
Valerie Zimmerman ◽  
James M. Steckelberg ◽  
Walter R. Wilson ◽  
...  
Keyword(s):  
Systematic Review ◽  
Infective Endocarditis ◽  
Propensity Score ◽  
Observational Studies ◽  
Propensity Score Analysis ◽  
Valve Surgery ◽  
Score Analysis

scholarly journals Role of routine drainage after hepatectomy in non-cirrhotic patients: A Multi-institutional French Propensity Score Analysis

HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e29
Author(s):  
M. Gelli ◽  
M.A. Allard ◽  
O. Farges ◽  
E. Vibert ◽  
F.-R. Pruvot ◽  
...  
Keyword(s):  
Propensity Score ◽  
Propensity Score Analysis ◽  
Score Analysis ◽  
Cirrhotic Patients

scholarly journals The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: A propensity score analysis

2008 ◽  
Vol 59 (7) ◽  
pp. 989-995 ◽  
Author(s):  
Roopa Seshadri ◽  
Brian M. Feldman ◽  
Norman Ilowite ◽  
Gail Cawkwell ◽  
Lauren M. Pachman
Keyword(s):  
Propensity Score ◽  
Corticosteroid Therapy ◽  
Juvenile Dermatomyositis ◽  
Propensity Score Analysis ◽  
Score Analysis

Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3556-3556
Author(s):  
Maria Alessandra Calegari ◽  
Ina Valeria Zurlo ◽  
Michele Basso ◽  
Armando Orlandi ◽  
Maria Bensi ◽  
...  
Keyword(s):  
Propensity Score ◽  
Propensity Score Analysis ◽  
Chi Square ◽  
Treatment Line ◽  
Score Analysis ◽  
Secondary Endpoints ◽  
Retrospective Nature ◽  
Metastatic Sites ◽  
Ecog Ps

3556 Background: The optimal treatment for mCRC beyond 2nd line is still questioned. Recently, REG and TAS-102 showed to improve survival compared to BSC. While in real-world practice CTr/r is often considered in this setting, supporting evidences are limited. In absence of studies comparing all these strategies, we aimed to compare the prognostic performance of CTr/r, REG and TAS-102 in mCRC treated beyond 2nd line. Methods: mCRC pts progressing after at least 2 lines of CT, treated with CTr/r, REG or TAS-102 between Jan-10 and Jan-19 were considered eligible. The primary endpoint was OS; secondary endpoints were PFS and RR. Cox’s proportional hazard models for survivals were estimated. A propensity score (PS) adjustment for baseline characteristics was further accomplished for survival analysis. Results: The clinical data of 341 pts (CTr/r 133, REG 150, TAS-102 58) were retrospectively collected. At multivariate analysis type of treatment, ECOG PS, number of metastatic sites and treatment line independently correlated with OS ( p < .001, p .001, p < .001 and p .029, respectively). The mOS was 18.5 (95% CI, 14.3–22.7), 6 (95% CI, 5.6–9.5) and 7.6 months (95%CI, 5.6–9.5), for CTr/r, REG and TAS-102 group, respectively (log-rank p < .0001). mOS was significantly longer for pts receiving CTr/r than for those treated with REG/TAS-102 (15.8 vs 7.1 months; adjusted HR 1.96, 95% CI 1.44-2.66; p < .0001) at the PS analysis, adjusted for ECOG PS, number of metastatic sites and treatment line; 2-yrs OS was 34% and 11.6% for CTr/r and REG/TAS-102, respectively. PFS was significantly longer for pts receiving CTr/r than for those treated with REG/TAS-102 (5.5 vs 3.9 months; HR 1.45, 95% CI 1.11-1.91; p .006) at the PS analysis. Accordingly, RR was higher in pts receiving CTr/r compared to REG/TAS-102 (29.0 vs 1.5%; Chi-square p < .00001). Conclusions: Our analysis, although underpowered, generates the hypothesis of a superiority of CTr/r in comparison to REG or TAS-102, in both efficacy and activity. Given the retrospective nature of our analysis, and the potential role of selection bias in treatment assignment, a prospective validation is mandatory.

Sign in / Sign up

Export Citation Format

Share Document